Company intelligence / Profile preview

Fntp

Seoul, Seoul, South Koreafntp.org.uk ↗

Ownership: Private
Development stage: Commercial

Overview

FNCT Biotech is an early-stage biopharmaceutical company developing next-generation monoclonal antibody therapies targeting severe and incurable diseases such as pulmonary fibrosis. The company leverages advanced antibody engineering platforms with a focus on immune modulation. As of mid–2025, no clinical results have been published.

Therapeutic areas: Pulmonology
Modalities: Monoclonal antibodyCytokineSmall molecule
Industry: Biotech

Partnerships

Amgen Golden Ticket Awards recipient

Beyond the preview

Go deeper on Fntp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fntp.

Explore the full profile